The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Reyataz     methylN-[(1S)-1-[[(2S,3S)-3- hydroxy-4...

Synonyms: Zrivada, Atazanavir, Latazanavir, atazanavirum, CHEMBL1163, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Zrivada


High impact information on Zrivada


Chemical compound and disease context of Zrivada


Biological context of Zrivada


Anatomical context of Zrivada


Associations of Zrivada with other chemical compounds


Gene context of Zrivada


Analytical, diagnostic and therapeutic context of Zrivada


  1. Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype. Lankisch, T.O., Moebius, U., Wehmeier, M., Behrens, G., Manns, M.P., Schmidt, R.E., Strassburg, C.P. Hepatology (2006) [Pubmed]
  2. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. Naeger, L.K., Struble, K.A. AIDS (2006) [Pubmed]
  3. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. Murphy, R.L., Sanne, I., Cahn, P., Phanuphak, P., Percival, L., Kelleher, T., Giordano, M. AIDS (2003) [Pubmed]
  4. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. Haerter, G., Manfras, B.J., Mueller, M., Kern, P., Trein, A. AIDS (2004) [Pubmed]
  5. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Pellegrin, I., Breilh, D., Ragnaud, J.M., Boucher, S., Neau, D., Fleury, H., Schrive, M.H., Saux, M.C., Pellegrin, J.L., Lazaro, E., Vray, M. Antivir. Ther. (Lond.) (2006) [Pubmed]
  6. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Ribera, E., Azuaje, C., Lopez, R.M., Diaz, M., Feijoo, M., Pou, L., Crespo, M., Curran, A., Ocaña, I., Pahissa, A. AIDS (2006) [Pubmed]
  7. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. Noor, M.A., Flint, O.P., Maa, J.F., Parker, R.A. AIDS (2006) [Pubmed]
  8. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Weinheimer, S., Discotto, L., Friborg, J., Yang, H., Colonno, R. Antimicrob. Agents Chemother. (2005) [Pubmed]
  9. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., Nelson, M., Moyle, G., Gazzard, B., Pozniak, A. J. Antimicrob. Chemother. (2006) [Pubmed]
  10. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Zhou, H., Gurley, E.C., Jarujaron, S., Ding, H., Fang, Y., Xu, Z., Pandak, W.M., Hylemon, P.B. Am. J. Physiol. Gastrointest. Liver Physiol. (2006) [Pubmed]
  11. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. Wood, R., Phanuphak, P., Cahn, P., Pokrovskiy, V., Rozenbaum, W., Pantaleo, G., Sension, M., Murphy, R., Mancini, M., Kelleher, T., Giordano, M. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  12. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Le Tiec, C., Barrail, A., Goujard, C., Taburet, A.M. Clinical pharmacokinetics. (2005) [Pubmed]
  13. Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy. Bergersen, B.M. Drugs (2006) [Pubmed]
  14. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Holland, D.T., DiFrancesco, R., Connor, J.D., Morse, G.D. Therapeutic drug monitoring. (2006) [Pubmed]
  15. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Perloff, E.S., Duan, S.X., Skolnik, P.R., Greenblatt, D.J., von Moltke, L.L. Drug Metab. Dispos. (2005) [Pubmed]
  16. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. van Leeuwen, E., Ter Heine, R., van der Veen, F., Repping, S., Beijnen, J.H., Prins, J.M. Antimicrob. Agents Chemother. (2007) [Pubmed]
  17. Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells. Roucairol, C., Azoulay, S., Nevers, M.C., Créminon, C., Lavrut, T., Garraffo, R., Grassi, J., Burger, A., Duval, D. Antimicrob. Agents Chemother. (2007) [Pubmed]
  18. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Zhang, D., Chando, T.J., Everett, D.W., Patten, C.J., Dehal, S.S., Humphreys, W.G. Drug Metab. Dispos. (2005) [Pubmed]
  19. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Tomilo, D.L., Smith, P.F., Ogundele, A.B., Difrancesco, R., Berenson, C.S., Eberhardt, E., Bednarczyk, E., Morse, G.D. Pharmacotherapy (2006) [Pubmed]
  20. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. Haas, D.W., Zala, C., Schrader, S., Piliero, P., Jaeger, H., Nunes, D., Thiry, A., Schnittman, S., Sension, M. AIDS (2003) [Pubmed]
  21. Atazanavir. Goldsmith, D.R., Perry, C.M. Drugs (2003) [Pubmed]
  22. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Taburet, A.M., Piketty, C., Chazallon, C., Vincent, I., Gérard, L., Calvez, V., Clavel, F., Aboulker, J.P., Girard, P.M. Antimicrob. Agents Chemother. (2004) [Pubmed]
  23. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. Lucia, M.B., Golotta, C., Rutella, S., Rastrelli, E., Savarino, A., Cauda, R. J. Acquir. Immune Defic. Syndr. (2005) [Pubmed]
  24. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. Guiard-Schmid, J.B., Poirier, J.M., Bonnard, P., Meynard, J.L., Slama, L., Lukiana, T., Jaillon, P., Pialoux, G. AIDS (2005) [Pubmed]
  25. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Robinson, B.S., Riccardi, K.A., Gong, Y.F., Guo, Q., Stock, D.A., Blair, W.S., Terry, B.J., Deminie, C.A., Djang, F., Colonno, R.J., Lin, P.F. Antimicrob. Agents Chemother. (2000) [Pubmed]
WikiGenes - Universities